The Evolution and Prognosis of Moyamoya Disease

Launched by CHINESE PLA GENERAL HOSPITAL · Nov 11, 2022

Keywords

ClinConnect Summary

This clinical trial, titled "The Evolution and Prognosis of Moyamoya Disease," aims to better understand how Moyamoya disease (MMD) affects brain images and cognitive abilities over time. The researchers want to find out how to use imaging techniques to predict the progression of the disease and improve the way it is diagnosed and treated. This study could help doctors make more informed decisions in managing MMD, which is a condition that causes narrowing of blood vessels in the brain, leading to potential strokes and cognitive issues.

To participate in this trial, individuals must be between the ages of 10 and 60 and have been diagnosed with Moyamoya disease based on specific imaging tests. Participants should be able to understand and complete cognitive function tests. However, individuals with a history of severe brain issues, other neurological diseases, or certain medical devices may not be eligible. Those who join the study can expect to undergo imaging tests and cognitive assessments, helping researchers gather important information about the disease and its impact on patients.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Patients with MMD: Conventional angiography or MRI examination conforms to the Guidelines for Diagnosis and Treatment of MMD (Neurol Med Chir (Tokyo) 52, 245-266, 2012), It is characterized by stenosis or occlusion of the end of the internal carotid artery, anterior cerebral artery and/or the beginning of the middle cerebral artery of unknown cause, accompanied by dilatation of the perforating artery at the base of the brain or of capillaries on the surface of the brain, i.e., the formation of smoke vessels. Sign the informed consent. Older than 10 and younger than 60. The education level of patients reached primary school or above (years of education ≥6).
• Exclusion Criteria:
• • Patients with massive cerebral infarction, multiple paraventricular ischemic foci, or significantly enlarged ventricular hydrocephalus after intracerebral hemorrhage. Patients with vascular diseases caused by immune system disease. Patients can not cooperate to complete the cognitive function test. There are other neuropsychiatric diseases that affect cognitive function (such as Alzheimer's disease, Parkinson's disease, depression, anxiety disorder, cerebral hemorrhage, hydrocephalus, craniocerebral trauma, etc.). Patients with contraindications of magnetic resonance examination (patients with pacemakers, nerve stimulators, artificial metal heart valves and other metal foreign bodies) or unable to complete image collection.